REBECCA BOSS: Open Payments
NPI 1811549959 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,000 in 85 payments from 21 companies in 2025. Trend: 2023 $785 · 2024 $848 · 2025 $2,000
Food & beverage: $2,000
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 14 | $279 |
| GENZYME CORPORATION | 11 | $268 |
| Botanix SB Inc | 6 | $206 |
| ABBVIE INC. | 10 | $179 |
| Incyte Corporation | 6 | $157 |
| MERZ NORTH AMERICA, INC. | 2 | $153 |
| LEO Pharma Inc. | 5 | $123 |
| Regeneron Healthcare Solutions, Inc. | 4 | $105 |
| Almirall LLC | 4 | $99 |
| UCB, Inc. | 3 | $71 |
Products named: DUPIXENT, SOFDRA, OPZELURA, Xeomin, ADBRY, Bimzelx, NEMLUVIO, RINVOQ.
Industry payments across TX — which companies pay providers there.
